AxoGen Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
14,556.90
17,710.50
13,356.40
14,411.10
10,445.50
22,397
Depreciation, Depletion & Amortization
138.30
198.90
249.00
436.50
566.60
851
Other Funds
4,702.20
7,174.70
2,031.40
4,269.50
4,078.80
11,348
Funds from Operations
9,716.30
10,336.90
11,076.00
9,705.10
5,800.10
10,198
Changes in Working Capital
728.40
114.10
1,975.80
1,499.30
3,437.50
7,664
Net Operating Cash Flow
10,444.80
10,451.10
13,051.80
11,204.40
9,237.60
17,862
Capital Expenditures
244.00
594.00
555.50
1,189.60
1,292.20
Net Investing Cash Flow
244.00
594.00
555.50
1,189.60
1,292.20
Issuance/Reduction of Debt, Net
-
2,570.40
180.10
3,247.50
75.40
Net Financing Cash Flow
16,851.10
808.90
31,301.00
16,498.90
17,022.00
Net Change in Cash
6,162.30
11,854.00
17,693.70
4,104.90
6,492.20
Free Cash Flow
10,623.50
10,993.10
13,460.60
12,168.20
10,342.80
Change in Capital Stock
16,851.10
1,761.60
31,481.20
19,746.40
17,097.40

About AxoGen

View Profile
Address
13631 Progress Boulevard
Alachua Florida 32615
United States
Employees -
Website http://www.axogeninc.com
Updated 07/08/2019
AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provide products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator.